Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix hexa + Prevenar + Rotarix refers to the concomitant administration of three distinct pediatric vaccines. Infanrix hexa (GSK) is a hexavalent vaccine providing protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b. Prevenar (Pfizer), specifically Prevenar 13, is a 13-valent pneumococcal conjugate vaccine targeting Streptococcus pneumoniae. Rotarix (GSK) is a live, attenuated oral vaccine against rotavirus. This regimen is commonly used in infant immunization schedules, typically at 2, 4, and 6 months of age. While co-administration is standard practice to reduce the number of visits, clinical data indicates a potential increase in the incidence of fever and febrile convulsions when Infanrix hexa and Prevenar 13 are administered together compared to Infanrix hexa alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Infanrix hexa + Prevenar + Rotarix.